Europe Lymphangioleiomyomatosis Lam Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2021 –2028 |
 시장 규모(기준 연도) |
USD 33.98 Million |
 시장 규모(예측 연도) |
USD 45.85 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
유럽 림프관평활근종증(LAM) 시장, 질병 유형별(결절성 경화증 복합형, 산발성형 및 기타), 유형별(진단, 치료), 합병증별(기흉, 유미흉, 신장 종양, 흉막 삼출액 , 부기 및 체액 축적, 기타), 투여 경로별(경구, 비경구, 기타), 최종 사용자별(병원, 전문 진료소, 진단 센터, 재택 의료 및 기타), 유통 채널별(직접 입찰, 병원 약국, 소매 약국, 온라인 약국, 기타) 국가별(독일, 프랑스, 이탈리아, 영국, 스페인, 네덜란드, 러시아, 스위스, 터키, 벨기에, 유럽의 다른 국가) 산업 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 유럽 림프관평활근종증(LAM) 시장
유럽 림프관평활근종증(LAM) 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 4.1%의 CAGR로 성장하고 있으며 2020년 3,398만 달러에서 2028년까지 4,585만 달러에 도달할 것으로 예상한다고 분석합니다. 당뇨병 발병률 증가와 림프관평활근종증(LAM)에 대한 새로운 기술 발전의 성장은 예측 기간 동안 시장 수요를 촉진하는 주요 동인이 될 가능성이 높습니다.
림프관평활근종증(LAM)은 폐계, 신장계, 림프계에 영향을 미치는 희귀한 낭포성 만성 폐 질환입니다. 림프계는 림프액과 면역 세포를 몸 전체로 운반하는 역할을 하는 조정된 혈관 네트워크로 구성되어 있습니다. LAM은 여성에게 발생합니다. 20~40세의 여성이 LAM 진단을 받습니다. 결절성 경화증이 있는 여성의 약 30%가 LAM에 걸리기 쉽습니다. 이는 종종 결절성 경화증 복합체(TSC), TSC 1 유전자의 돌연변이로 인해 발생합니다. 고립성 또는 산발성 LAM은 LAM이 단독으로 발생하는 것을 말합니다.
림프관세포성 근종증은 TSC 1과 TSC 2라는 두 유전자의 돌연변이 변화로 인해 발생합니다. 첫 번째 돌연변이 형태는 유전적이며 결절성 경화증 환자에게 발생합니다. 두 번째 형태는 결절성 경화증과 관련이 없으며 산발성 LAM이라고 합니다. 산발성 LAM이 있는 사람도 유전적 돌연변이가 있지만 유전자 돌연변이는 유전되지 않으며 자녀에게 유전되지 않습니다. 이러한 유전자 돌연변이가 발생하는 이유는 불분명합니다.
만성 낭포성 폐질환의 유병률 증가, 여성의 혈관근지방종과 결절성 경화증의 증가, 임상 시험의 증가는 림프관평활근종증(LAM) 시장 성장의 길을 닦았습니다. 게다가 신흥 경제권에서 림프관평활근종증(LAM)의 성장 잠재력과 제품(진단 기계와 제네릭 의약품)의 증가는 림프관평활근종증(LAM) 시장 성장을 뒷받침합니다. 그러나 LAM 치료 비용의 증가, 부과된 엄격한 규제, 림프관평활근종증(LAM)이 개발도상국에서 접근이 불가능하다는 것은 시장 성장을 방해할 수 있는 제약입니다. 사용된 재료의 불일치는 시장 성장을 방해할 수 있는 제약입니다.
유럽 림프관평활근종증(LAM) 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 기회 분석을 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
유럽 림프관평활근종증(LAM) 시장 범위 및 시장 규모
유럽 림프관평활근종증(LAM) 시장은 질병 유형, 유형, 합병증, 투여 경로, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간 성장을 통해 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
- 질병 유형을 기준으로 유럽 림프관평활근종증(LAM) 시장은 결절성 경화증 복합체 LAM과 산발성 LAM으로 구분됩니다. 2021년에는 결절성 경화증 복합체 LAM 부문이 유럽 림프관평활근종증(LAM) 시장을 지배하고 있으며, 유럽 여성 인구에서 혈관근지방종이 증가함에 따라 이 부문이 시장을 지배할 것으로 예측됩니다.
- On the basis of type, the Europe lymphangioleiomyomatosis (LAM ) market is segmented into diagnosis and treatment. The diagnosis segment is further segmented into blood test (vascular endothelial growth factor d (vegf-d)) and imaging test, lung function test, lung biopsy test, and others. The imaging test is further sub segmented into chest x-rays, chest CT scans, MRI of abdomen and others. The lung biopsy test is further sub-segmented into transbronchial lung biopsy and video-assisted thorascopic lung biopsy. The treatment segment is further segmented into medication, oxygen therapy, and lung transplantation. The medication is further sub-segmented into mtor inhibitors and bronchodilators. The mTOR inhibitors are further sub-segmented into sirolimus/ rapamycin, everolimus and others. The bronchodilators are further sub-segmented into albuterol, formoterol, salmeterol and others. The lung transplantation is further sub-segmented into single-lung transplantation (SLT) and bilateral lung transplantation (BLT). In 2021 the treatment segment is dominating theEuropelymphangioleiomyomatosis (LAM) market owing to the rise in the number of cases and availability of generics, diagnostic and lung transplants.
- On the basis of complications, the Europe lymphangioleiomyomatosis (LAM) market is segmented into pneumothorax, chylothorax, kidney tumor, pleural effusions, swelling & fluid build-up, and others. In 2021, the pneumothorax segment is expected to dominate theEuropelymphangioleiomyomatosis (LAM) market due to the increased prevalence of female patients suffering from the pulmonary disorder and timely diagnosis and treatment are predicted to dominate the market.
- On the basis of route of administration, the Europe lymphangioleiomyomatosis (LAM) market is segmented into oral, parenteral. The oral segment is further segmented into tablets, capsules, and others. The parenteral segment is further segmented into intravenous subcutaneous and others. In 2021, the oral segment is expected to dominate theEuropelymphangioleiomyomatosis (LAM) market due to the ease of absorption, and availability of oral medications in Europe are predicted to dominate the market.
- On the basis of end user, theEurope lymphangioleiomyomatosis (LAM) market is segmented into hospitals, specialty clinics, diagnostic centers, home healthcare and others. In 2021, the hospitals segment is expected to dominate theEuropelymphangioleiomyomatosis (LAM) market due to the increased need for treatment of lymphangioleiomyomatosis and the improvement in healthcare infrastructure in Europe are predicted to dominate the market.
- On the basis of distribution channel, the Europelymphangioleiomyomatosis (LAM) market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. In 2021, the direct tender segment is expected to dominate theEuropelymphangioleiomyomatosis (LAM) market due to the rise in access to sirolimus medications, the surge in the number of prescriptions daily and the rise in the number of contacts for the distribution of diagnostic medications and bronchodilators are predicted to dominate the market.
Europe Lymphangioleiomyomatosis (LAM) Market Country Level Analysis
The Europe lymphangioleiomyomatosis (LAM) market is analysed and market size information is provided by product & services, sample type, process, application, compound library size, end user, and distribution channel.
The countries covered in the Europe lymphangioleiomyomatosis (LAM)market report are the Germany, France, Italy, U.K., Spain, Switzerland, Russia, Netherlands, Belgium, Turkey & rest of Europe.
Europe is expected to grow with the CAGR in the forecasted periods as in the growing R&D activities in the pharma and biotech sector. Germany is expected to dominate in the market in the Europe market. Germany is one of the leading countries due to the presence of major market players and increased technological advancement in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
The Growth Potential for Lymphangioleiomyomatosis (LAM)in Emerging Economies and the Strategic Initiatives by Market Players are creating new Opportunities in the Europe Lymphangioleiomyomatosis (LAM) Market
Europe lymphangioleiomyomatosis (LAM) market also provides you with detailed market analysis for every country growth in particular industry with lymphangioleiomyomatosis (LAM)sales, impact of advancement in the lymphangioleiomyomatosis (LAM), and changes in regulatory scenarios with their support for the lymphangioleiomyomatosis (LAM)market. The data is available for historic period 2019 to 2028.
Competitive Landscape and Europe Lymphangioleiomyomatosis (LAM) Market Share Analysis
유럽 림프관평활근종증(LAM) 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭, 숨결, 응용 분야 우세, 기술 수명선 곡선이 포함된 세부 정보입니다. 위에 제공된 데이터 포인트는 림프관평활근종증(LAM) 시장과 관련된 회사의 초점에만 관련됩니다.
유럽 림프관평활근종증(LAM)을 제공하는 주요 회사는 Pfizer Inc, Intas Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, Dr. Reddy's Laboratories Ltd, Novartis AG, Hikma Pharmaceuticals PLC, TransMedics Group, Inc, Terumo Corporation, HERSILL, Care Dx, XVIVO, Taj Pharmaceuticals Limited입니다.
시장 참여자들의 전략적 이니셔티브와 림프관평활근종증(LAM)에 대한 새로운 기술적 발전이 만성 상처 치료의 격차를 메우고 있습니다.
예를 들어,
- 2020년 1월, Amneal Pharmaceuticals LLC는 Amneal Pharmaceuticals의 자회사인 Impax Laboratories, LLC에서 사용하는 에피네프린 자동 주사기를 사용하도록 식품의약국 FDA에 발표했습니다. 경고에는 이 장치가 환자에게 이중 복용량을 전달할 가능성이 있다고 명시되어 있습니다. 이 개념은 결절성 경화증 복합체 LAM을 앓고 있는 환자의 건강을 해칠 수 있으며 에피네프린 자동 주사기의 생산을 방해할 수 있습니다.
협력, 합작사업 및 기타 시장 참여자의 전략은 유럽 림프관평활근종증(LAM) 시장에서 회사 시장을 확대하고 있으며, 이를 통해 기업은 치료 제품에 대한 제공을 개선하는 데 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET INDICATION COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 EUROPE LYMPHANGIOLEIOMYOMATOSIS MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISE IN PREVALENCE OF CHRONIC CYSTIC LUNG DISORDERS
7.1.2 RISE OF ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) IN WOMEN
7.1.3 RISE IN GOVERNMENT INITIATIVES AND ORGANIZATIONS
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 HEALTHCAREREIMBURSEMENTFOR LYMPHANGIOLEIOMYOMATOSIS
7.2 RESTRAINTS
7.2.1 RISE IN COST FOR LYMPHANGIOLEIOMYOMATOSIS (LAM) TREATMENT
7.2.2 AVAILABILITY OF ALTERNATIVES
7.2.3 HIGH COMPLEXITY IN LAM
7.2.4 STRICT REGULATORY FRAMEWORK
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE
7.3.2 RISE IN PRODUCT APPROVALS
7.3.3 USE OF NON-INVASIVE PROCEDURE
7.4 CHALLENGES
7.4.1 SIDE EFFECTS FOUND DURING LAM TREATMENT
7.4.2 PATIENT COMPLIANCE DURING THE TREATMENT OF LAM
8 IMPACT OF COVID-19 ON EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.1 ANALYSIS ON IMPACT OF COVID-19 ON LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.2 IMPACT ON PRICE OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.3 IMPACT ON DEMAND OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.4 IMPACT ON SUPPLY CHAIN OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.5 STRATEGIC DECISIONS BY MANUFACTURERS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.6 CONCLUSION
9 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 TUBEROUS SCLEROSIS COMPLEX LAM
9.3 SPORADIC LAM
10 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE
10.1 OVERVIEW
10.2 TREATMENT
10.2.1 MEDICATION
10.2.2 MTOR INHIBITORS
10.2.3 SIROLIMUS/ RAPAMYCIN
10.2.4 EVEROLIMUS
10.2.5 OTHERS
10.2.6 BRONCHODILATORS
10.2.7 ALBUTEROL
10.2.8 SALMETEROL
10.2.9 GLYCOPYRROLATE
10.2.10 OTHERS
10.2.11 OXYGEN THERAPY
10.2.12 LUNG TRANSPLANTATION
10.2.13 BILATERAL LUNG TRANSPLANTATION (BLT)
10.2.14 SINGLE-LUNG TRANSPLANTATION (SLT)
10.3 DIAGNOSIS
10.3.1 IMAGING TEST
10.3.2 CHEST X-RAYS
10.3.3 CHEST CT SCANS
10.3.4 MRI OF ABDOMEN
10.3.5 OTHERS
10.3.6 LUNG FUNCTION TEST
10.3.7 BLOOD TEST (VASCULAR ENDOTHELIAL GROWTH FACTOR D (VEGF-D))
10.3.8 LUNG BIOPSY
10.3.9 VIDEO-ASSISTED THORASCOPIC LUNG BIOPSY
10.3.10 TRANSBRONCHIAL LUNG BIOPSY
10.3.11 OTHERS
10.3.12 OTHERS
11 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS
11.1 OVERVIEW
11.2 PNEUMOTHORAX
11.3 PLEURAL EFFUSIONS
11.4 KIDNEY TUMOR
11.5 CHYLOTHORAX
11.6 SWELLING & FLUID BUILD-UP
11.7 OTHERS
12 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLET
12.2.2 CAPSULES
12.2.3 OTHERS
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 SUBCUTANEOUS
12.3.3 OTHERS
13 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 DIAGNOSTIC CENTER
13.5 HOME HEALTHCARE
13.6 OTHERS
14 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 HOSPITAL PHARMACIES
14.4 RETAIL PHARMACIES
14.5 ONLINE PHARMACIES
14.6 OTHERS
15 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION
15.1 OVERVIEW
15.2 EUROPE
15.2.1 GERMANY
15.2.2 FRANCE
15.2.3 U.K.
15.2.4 HUNGARY
15.2.5 LITHUANIA
15.2.6 AUSTRIA
15.2.7 IRELAND
15.2.8 NORWAY
15.2.9 POLAND
15.2.10 ITALY
15.2.11 SPAIN
15.2.12 RUSSIA
15.2.13 TURKEY
15.2.14 NETHERLANDS
15.2.15 SWITZERLAND
15.2.16 REST OF EUROPE
16 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 COMPANY PROFILE
17.1 TERUMO CORPORATION
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 CAREDX, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 PFIZER INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 NOVARTIS AG
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 APOTEX INC
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.7 AMNEAL PHARMACEUTICALS LLC
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 HIKMA PHARMACEUTICALS PLC
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 HERSILL
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 HOME OXYGEN COMPANY
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 INTAS PHARMACEUTICALS, LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 INOGEN INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 MORGAN SCIENTIFIC
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 PULMONE ADVANCED MEDICAL DEVICES
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 PARAGONIX TECHNOLOGIES, INC
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENTS
17.16 DR REDDY’S LABORATORIES LTD.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 SANDOR
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD)
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 TRANSMEDICS GROUP INC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 TAJ PHARMACEUTICALS LTD
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENT
17.21 XVIVO
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: PIPELINE ANALYSIS
TABLE 2 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 EUROPE TUBEROUS SCLEROSIS COMPLEX LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 EUROPE SPORADIC LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 EUROPE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 EUROPE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 EUROPE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 EUROPE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 EUROPE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 EUROPE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 17 EUROPE PNEUMOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE PLEURAL EFFUSIONS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE KIDNEY TUMOR IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE CHYLOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 EUROPE SWELLING & FLUID BUILD-UP IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION , 2019-2028 (USD MILLION)
TABLE 26 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 EUROPE HOSPITALS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE SPECIALTY CLINICS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE DIAGNOSTIC CENTER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 EUROPE HOME HEALTHCARE IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 35 EUROPE DIRECT TENDER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE HOSPITAL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE RETAIL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 EUROPE ONLINE PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 42 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 43 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 44 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 45 EUROPE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 46 EUROPE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 EUROPE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 EUROPE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 EUROPE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 EUROPE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 53 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 56 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 59 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 GERMANY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 GERMANY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 GERMANY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 GERMANY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 GERMANY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 GERMANY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 GERMANY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 GERMANY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 69 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 GERMANY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 GERMANY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 75 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 FRANCE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 FRANCE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 FRANCE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 FRANCE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 FRANCE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 FRANCE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 FRANCE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 FRANCE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 85 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 86 FRANCE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 87 FRANCE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 88 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 89 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 90 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 91 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 U.K. TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 U.K. MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 U.K. MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 U.K. BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 U.K. LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 97 U.K. DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 U.K. IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 99 U.K. LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 100 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 101 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 102 U.K. ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 103 U.K. PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 104 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 105 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 106 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 107 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 HUNGARY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 HUNGARY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 HUNGARY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 HUNGARY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 HUNGARY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 HUNGARY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 HUNGARY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 HUNGARY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 117 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 118 HUNGARY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 119 HUNGARY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 121 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 122 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 123 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 124 LITHUANIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 LITHUANIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 LITHUANIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 LITHUANIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 LITHUANIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 LITHUANIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 LITHUANIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 LITHUANIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 133 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 134 LITHUANIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 135 LITHUANIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 136 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 137 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 138 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 139 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 140 AUSTRIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 141 AUSTRIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 142 AUSTRIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 143 AUSTRIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 144 AUSTRIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 145 AUSTRIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 146 AUSTRIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 AUSTRIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 149 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 150 AUSTRIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 151 AUSTRIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 152 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 153 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 154 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 155 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 IRELAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 IRELAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 IRELAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 IRELAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 160 IRELAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 161 IRELAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 162 IRELAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 163 IRELAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 164 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 165 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 IRELAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 167 IRELAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 168 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 169 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 170 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 171 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 NORWAY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 NORWAY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 NORWAY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 NORWAY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 NORWAY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 NORWAY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 NORWAY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 179 NORWAY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 181 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 182 NORWAY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 NORWAY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 185 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 186 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 187 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 188 POLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 189 POLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 POLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 POLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 POLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 POLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 POLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 POLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 197 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 198 POLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 199 POLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 200 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 201 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 202 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 203 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 ITALY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 205 ITALY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 206 ITALY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 207 ITALY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 208 ITALY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 209 ITALY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 210 ITALY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 211 ITALY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 212 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 213 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 214 ITALY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 215 ITALY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 216 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 217 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 218 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 219 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 220 SPAIN TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 221 SPAIN MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 222 SPAIN MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 223 SPAIN BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 224 SPAIN LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 SPAIN DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 SPAIN IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 SPAIN LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 228 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 229 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 SPAIN ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 231 SPAIN PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 232 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 233 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 234 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 235 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 236 RUSSIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 237 RUSSIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 238 RUSSIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 239 RUSSIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 240 RUSSIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 241 RUSSIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 242 RUSSIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 RUSSIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 245 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 246 RUSSIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 247 RUSSIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 248 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 249 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 250 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 251 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 252 TURKEY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 253 TURKEY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 254 TURKEY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 255 TURKEY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 256 TURKEY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 257 TURKEY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 258 TURKEY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 259 TURKEY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 260 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 261 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 262 TURKEY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 263 TURKEY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 264 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 265 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 266 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 267 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 NETHERLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 NETHERLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 NETHERLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 271 NETHERLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 272 NETHERLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 273 NETHERLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 274 NETHERLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 275 NETHERLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 276 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 277 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 278 NETHERLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 279 NETHERLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 280 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 281 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 282 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 283 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 SWITZERLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 285 SWITZERLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 286 SWITZERLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 287 SWITZERLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 288 SWITZERLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 289 SWITZERLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 SWITZERLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 291 SWITZERLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 292 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 293 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 294 SWITZERLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 295 SWITZERLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 296 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 297 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 298 REST OF EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
FIGURE 2 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: EUROPE VS REGIONAL ANALYSIS
FIGURE 5 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: MARKET INDICATION COVERAGE GRID
FIGURE 10 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF CHRONIC CYSTIC LUNG DISORDER , RISE IN CLINICAL TRIALS AND PRESENCE OF HEALTHCARE REIMBURSEMENT IS EXPECTED TO DRIVE THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKETIN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 DISEASE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET AND IS ALSO EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
FIGURE 15 PREVALENCE OF CHRONIC PULMONARY (LUNG) CYSTS, WHICH INCREASES WITH AGE
FIGURE 16 PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISORDER , HIGHER IN FEMALES
FIGURE 17 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE, 2020
FIGURE 18 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY TYPE, 2020
FIGURE 19 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COMPLICATIONS, 2020
FIGURE 20 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 21 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY END USER, 2020
FIGURE 22 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 23 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SNAPSHOT (2020)
FIGURE 24 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2020)
FIGURE 25 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2021 & 2028)
FIGURE 26 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2020 & 2028)
FIGURE 27 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 28 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SNAPSHOT (2020)
FIGURE 29 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2020)
FIGURE 30 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 31 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 32 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 33 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
